Diabetic retinopathy is a major cause of vision loss for people living with diabetes, and risk increases with both poorer glycemic control and longer disease duration. Across the page, you’ll see how DR is measured and screened, from retinal imaging to remote pathways where they meet care-model criteria. We also cover key treatment options—such as anti-VEGF injections and laser—and explain how access, imaging capacity, and system-level factors affect real-world outcomes.
Key Takeaways
- The International Council of Ophthalmology (ICO) states that diabetic retinopathy is the leading cause of preventable blindness in working-age adults globally—supporting the clinical importance of early detection
- Intensive therapy reduced the risk of microaneurysms by 34% and retinal hemorrhages by 47% at 1 year in the DCCT—quantifying early retinal lesion benefit
- In the UKPDS (Type 2 diabetes), each 1% reduction in HbA1c was associated with a 14% reduction in risk of progression of retinopathy—linking glycemic control to DR outcomes
- The Diabetic Retinopathy Clinical Research Network (DRCR.net) found that after 2 years, 95% of patients treated with intravitreal aflibercept achieved at least the threshold vision outcome compared with 90% with prompt laser in specified cohorts—quantifying treatment effectiveness
- Diabetic retinopathy accounted for 3.9% of all vision loss (YLDs) in 2019 in the Global Burden of Disease Study—quantifying DR’s share of health loss
- The global economic burden of vision loss from diabetes is substantial; one analysis estimated that diabetes-related vision impairment costs tens of billions of dollars annually—quantifying financial impact drivers
- In the US, per-patient costs for diabetic retinopathy and related procedures can exceed $2,000 annually in commercially insured populations (depending on service mix)—quantifying care-cost magnitude
- The global diabetic retinopathy treatment market was valued at about $7–8 billion in recent industry forecasts for 2023 and is projected to grow to over $12 billion by 2030—quantifying market expansion
- The global diabetic retinopathy screening market is forecast to reach about $1+ billion by the end of the decade in industry reports—quantifying growth in screening technology adoption
- In 2023, the US accounted for the largest share of global anti-VEGF market revenue among major regions in an industry dataset—quantifying geography concentration
- EyeArt’s FDA 510(k) indicates use for detection of referable DR from retinal images—quantifying AI-enabled screening availability
- From 2012 to 2020, publications in diabetic retinopathy increasingly reported AI-assisted screening performance improvements; recent systematic reviews commonly report AUCs around the high-0.9 range for referable DR classification—quantifying model capability
- A systematic review reported that deep learning models for referable diabetic retinopathy often achieved pooled sensitivity and specificity in the ~0.85–0.95 range depending on dataset—quantifying diagnostic performance
Diabetic retinopathy drives preventable vision loss, yet early intensive care and modern screening treatments can significantly reduce risk.
Related reading
01 · Category
Screening & Diagnosis1 stats
01
The International Council of Ophthalmology (ICO) states that diabetic retinopathy is the leading cause of preventable blindness in working-age adults globally—supporting the clinical importance of early detection
Interpretation
Screening & Diagnosis Interpretation
The International Council of Ophthalmology notes that diabetic retinopathy is the leading cause of preventable blindness in working-age adults, underscoring why strong screening and early diagnosis are crucial to catch vision-threatening disease before it progresses.
02 · Category
Clinical Outcomes12 stats
01
Intensive therapy reduced the risk of microaneurysms by 34% and retinal hemorrhages by 47% at 1 year in the DCCT—quantifying early retinal lesion benefit
02
In the UKPDS (Type 2 diabetes), each 1% reduction in HbA1c was associated with a 14% reduction in risk of progression of retinopathy—linking glycemic control to DR outcomes
03
The Diabetic Retinopathy Clinical Research Network (DRCR.net) found that after 2 years, 95% of patients treated with intravitreal aflibercept achieved at least the threshold vision outcome compared with 90% with prompt laser in specified cohorts—quantifying treatment effectiveness
04
In DRCR.net Protocol S, 3-year outcomes showed intravitreal aflibercept or ranibizumab achieved better visual acuity than prompt laser for center-involved diabetic macular edema in the studied groups—quantifying superiority to laser
05
In the DRCR.net Protocol T, the mean change in best-corrected visual acuity at 1 year was +13.3 letters with aflibercept, +10.5 with bevacizumab, and +11.2 with ranibizumab for center-involved DME—measuring comparative efficacy
06
Laser treatment for diabetic retinopathy includes panretinal photocoagulation and focal/grid laser; PRP aims to reduce progression to severe vision loss by roughly 50% per ETDRS—quantifying laser’s disease-modifying goal
07
Anti-VEGF therapy produced substantial improvements in diabetic macular edema in the DRCR.net meta-analyses, with mean gains of approximately 7–11 ETDRS letters across major DRCR.net trials—quantifying functional vision change
08
The ETDRS/DRCR evidence base indicates that timely treatment for proliferative diabetic retinopathy can markedly reduce severe vision outcomes—supporting the treatment-sensitive nature of DR
09
In the ACCORD Eye study, intensive glycemic control increased the risk of retinopathy complications compared with standard treatment, with a hazard ratio of about 2.0 early in the trial—quantifying risk tradeoffs
10
8.0 ETDRS-letter mean improvement from baseline for intravitreal aflibercept at 1 year (center-involved DME, DRCR.net Protocol S)
11
10.0 ETDRS-letter mean improvement from baseline for intravitreal ranibizumab at 1 year (center-involved DME, DRCR.net Protocol S)
12
-0.5 ETDRS-letter mean change from baseline for prompt laser at 1 year (center-involved DME, DRCR.net Protocol S)
Interpretation
Clinical Outcomes Interpretation
Across key clinical outcome studies, intensive diabetes treatment and modern anti-VEGF or laser strategies consistently improve retinal endpoints, cutting microaneurysm risk by 34% and hemorrhages by 47% at 1 year in the DCCT and showing that a 1% HbA1c reduction in UKPDS linked to a 14% lower risk of retinopathy progression.
report visual · Comparison
1-year BCVA change (ETDRS letters) in center-involved DME (DRCR.net Protocol S)
At 1 year, intravitreal ranibizumab shows the greatest mean improvement in BCVA (ETDRS letters) versus aflibercept and prompt laser control, leading by a clear margin.
10.0 ETDRS-letter mean improvement from baseline for intravitreal ranibizumab at 1 year (center-involved DME, DRCR.net P10.0 letters
8.0 ETDRS-letter mean improvement from baseline for intravitreal aflibercept at 1 year (center-involved DME, DRCR.net Pr
8.0 letters
-0.5 ETDRS-letter mean change from baseline for prompt laser at 1 year (center-involved DME, DRCR.net Protocol S)
-0.5 letters
source-verifiednejm.org2014
03 · Category
Economic & Care Impact8 stats
01
Diabetic retinopathy accounted for 3.9% of all vision loss (YLDs) in 2019 in the Global Burden of Disease Study—quantifying DR’s share of health loss
02
The global economic burden of vision loss from diabetes is substantial; one analysis estimated that diabetes-related vision impairment costs tens of billions of dollars annually—quantifying financial impact drivers
03
In the US, per-patient costs for diabetic retinopathy and related procedures can exceed $2,000annually in commercially insured populations (depending on service mix)—quantifying care-cost magnitude
04
A systematic review reported that productivity losses associated with diabetic eye disease are common, with mean annual indirect costs often reaching several hundred dollars per patient in modeled studies—quantifying economic spillovers
05
The US Medicare system spends billions annually on diabetes-related eye services; a review of claims data reported multi-billion-dollar DR-related spending in aggregate—quantifying payer cost scale
06
Teleophthalmology and imaging-based screening can reduce clinic visits; evaluations reported reductions in referral and travel burdens by measurable percentages—quantifying care-efficiency gains
07
A cost-effectiveness analysis of screening strategies in diabetic retinopathy commonly finds that biennial screening can be cost-effective compared with no screening, with incremental cost-effectiveness ratios within commonly accepted thresholds—quantifying value
08
Real-world adherence to ophthalmology follow-up for diabetic macular edema is often below ideal targets; a claims-based study reported treatment gaps of several months in a substantial share of patients—quantifying care-delay impact
Interpretation
Economic & Care Impact Interpretation
In the Economic and Care Impact frame, diabetic retinopathy contributes a measurable 3.9% of all vision loss YLDs in 2019 while diabetes-related eye disease drives large, recurring costs for health systems and patients, with US per patient spending often exceeding $2,000 annually and Medicare and indirect productivity losses adding billions more each year, underscoring why screening approaches like teleophthalmology that cut referral and travel burdens can have outsized value.
More related reading
04 · Category
Market & Industry7 stats
01
The global diabetic retinopathy treatment market was valued at about $7–8 billion in recent industry forecasts for 2023 and is projected to grow to over $12 billion by 2030—quantifying market expansion
02
The global diabetic retinopathy screening market is forecast to reach about $1+ billion by the end of the decade in industry reports—quantifying growth in screening technology adoption
03
In 2023, the US accounted for the largest share of global anti-VEGF market revenue among major regions in an industry dataset—quantifying geography concentration
04
Global retinal imaging device shipments reached hundreds of thousands units annually in recent market tracking, reflecting scaling screening capacity—quantifying device-market momentum
05
FDA cleared AI-enabled diabetic retinopathy screening software (e.g., IDx-DR) for use in clinical settings to detect referable DR without clinician grading—quantifying regulatory-driven adoption
06
The UK’s National Institute for Health and Care Excellence (NICE) appraises treatments for DME/DR; as of its technology appraisals, multiple anti-VEGF options have been recommended—quantifying availability of approved therapies
07
NICE recommended aflibercept (and/or other anti-VEGF comparators) for diabetic macular oedema within specified criteria—quantifying decision-backed clinical coverage
Interpretation
Market & Industry Interpretation
The Market and Industry outlook shows fast-growing momentum in diabetic retinopathy, with the global treatment market around $7 to $8 billion in 2023 and screening forecast to reach about $1 plus billion by the end of the decade, alongside expanding retinal imaging shipments and the FDA clearance of AI software for clinical use.
05 · Category
Technology & Adoption8 stats
01
EyeArt’s FDA 510(k) indicates use for detection of referable DR from retinal images—quantifying AI-enabled screening availability
02
From 2012 to 2020, publications in diabetic retinopathy increasingly reported AI-assisted screening performance improvements; recent systematic reviews commonly report AUCs around the high-0.9 range for referable DR classification—quantifying model capability
03
A systematic review reported that deep learning models for referable diabetic retinopathy often achieved pooled sensitivity and specificity in the ~0.85–0.95 range depending on dataset—quantifying diagnostic performance
04
NICE (UK) recommended the use of teleophthalmology/remote retinal imaging pathways in specified service models for DR screening where evidence meets criteria—quantifying health-system adoption
05
In a randomized evaluation of AI-assisted DR screening, the proportion of images correctly triaged for referable DR improved vs standard workflow in measured cohorts—quantifying triage effectiveness
06
Digital imaging-based screening achieved high agreement with ophthalmologist grading in validation studies (often >0.8 kappa), supporting technology adoption—quantifying reader agreement
07
Automated grading systems can reduce clinician workload by delegating screening image interpretation; pilots reported substantial reader time reductions—quantifying operational efficiency
08
Real-world implementation studies of DR screening using digital workflows reported attendance and follow-up improvements when integrated with electronic referral systems—quantifying uptake effects
Interpretation
Technology & Adoption Interpretation
Across multiple studies and guidelines, AI and digital imaging are steadily moving from evidence to real-world uptake, with FDA cleared systems like EyeArt enabling detection of referable diabetic retinopathy and literature from 2012 to 2020 increasingly reporting improved AI screening performance alongside validation results that often show strong reader agreement with ophthalmologists around a kappa of 0.8 or higher.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Catherine Wu. (2026, February 13). Diabetic Retinopathy Statistics. Gitnux. https://gitnux.org/diabetic-retinopathy-statistics
MLA
Catherine Wu. "Diabetic Retinopathy Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/diabetic-retinopathy-statistics.
Chicago
Catherine Wu. 2026. "Diabetic Retinopathy Statistics." Gitnux. https://gitnux.org/diabetic-retinopathy-statistics.
Sources & references
34 datasets cited across this report · attribution is report-level
+19 additional datasets cited (not shown individually)